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Furthermore, a proportion of PMR patients may subsequently evolve into RA. 
The aim of this study was to examine the clinical characteristics of PMR 
patients in a Chinese cohort compared to a Caucasian series. Patients 
diagnosed to have PMR during 1997–2008 were reviewed for clinical features 
and compared to a reported Caucasian series. Rheumatoid factor (RF) and 
anticyclic citrullinated peptide (CCP) antibodies were determined by 
immunonephelometry and enzyme-linked immunosorbent assay, respectively. 
Forty-four patients of southern Chinese origin were diagnosed to have PMR 
according to specialist opinion. Seventy-five percent of patients (n = 33) were 
>65 years of age at diagnosis (mean ± standard deviation, 75.8 ± 
9.6 years). The commonest feature at disease onset was elevated erythrocyte 
sedimentation rate >40 mm/h (100% vs. 95.7%; p = 0.17) and bilateral 
shoulder pain or stiffness (95.5% vs. 90.8%; p = 0.31), comparable in 
frequency to the Caucasian cohort. However, Chinese patients had significantly 
longer duration of symptoms before diagnosis (p < 0.001) but less bilateral 
upper arm tenderness (p < 0.001) and generalized stiffness (p = 0.01). 
Twelve (27.3%) patients evolved into RA after a median duration of 2 months 
from onset of PMR. RF and anti-CCP antibodies were positive in 66.7% and 
60% of these patients compared to 9.4% and 6.2%, respectively, among those 
who did not evolve into RA during the period observed. Chinese patients with 
PMR have modestly different clinical profile compared to the Caucasian 
counterpart. RF and anti-CCP antibodies were more likely to be present in 
those who subsequently developed into RA. 
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10 Abstract Polymyalgia rheumatica (PMR) is diagnosed
11 based on clinical features that may overlap with other
12 rheumatic conditions like rheumatoid arthritis (RA). Fur-
13 thermore, a proportion of PMR patients may subsequently
14 evolve into RA. The aim of this study was to examine the
15 clinical characteristics of PMR patients in a Chinese cohort
16 compared to a Caucasian series. Patients diagnosed to have
17 PMR during 1997–2008 were reviewed for clinical features
18 and compared to a reported Caucasian series. Rheumatoid
19 factor (RF) and anticyclic citrullinated peptide (CCP)
20 antibodies were determined by immunonephelometry and
21 enzyme-linked immunosorbent assay, respectively. Forty-
22 four patients of southern Chinese origin were diagnosed to
23 have PMR according to specialist opinion. Seventy-five
24 percent of patients (n=33) were >65 years of age at
25 diagnosis (mean±standard deviation, 75.8±9.6 years). The
26 commonest feature at disease onset was elevated erythro-
27 cyte sedimentation rate >40 mm/h (100% vs. 95.7%;
28 p=0.17) and bilateral shoulder pain or stiffness (95.5% vs.
29 90.8%; p=0.31), comparable in frequency to the Caucasian
30 cohort. However, Chinese patients had significantly longer
31 duration of symptoms before diagnosis (p<0.001) but less
32 bilateral upper arm tenderness (p<0.001) and generalized
33 stiffness (p=0.01). Twelve (27.3%) patients evolved into
34 RA after a median duration of 2 months from onset of
35PMR. RF and anti-CCP antibodies were positive in 66.7%
36and 60% of these patients compared to 9.4% and 6.2%,
37respectively, among those who did not evolve into RA
38during the period observed. Chinese patients with PMR
39have modestly different clinical profile compared to the
40Caucasian counterpart. RF and anti-CCP antibodies were
41more likely to be present in those who subsequently
42developed into RA.
43Keywords Anticyclic citrullinated peptide antibodies .
44Polymyalgia rheumatica . Rheumatoid arthritis
45Introduction
46Polymyalgia rheumatica (PMR) is an inflammatory condition
47of unknown etiology commonly found in the elderly and is
48often associated with impaired quality of life of these patients
49[1]. The diagnosis of PMR is mainly based on clinical
50features such as aches and stiffness in the cervical region,
51shoulder, and pelvic girdles. There is yet no specific
52serological marker for this condition. A recent prospective
53study suggested that PMR is a heterogeneous condition with
54variable responsiveness to corticosteroid treatment [1]. There
55is still inconsistency with regard to the guideline on
56diagnosis, management, and disease response measures in
57this condition [2]. A number of diagnostic criteria have been
58proposed to classify PMR [3–5], and the criteria proposed by
59Bird et al. [3] have been more widely used because of their
60higher sensitivity [6]. The diagnosis of PMR is regarded as
61definite if the patient fulfills three or more of the criteria
62including age >65 years, time from onset of symptoms to
63full-blown disease of less than 2 weeks, bilateral shoulder
64pain or stiffness, bilateral upper arm tenderness, stiffness
65>1 h, depression and/or weight loss, and erythrocyte
W. L. Li :Y. Lo :W. S. Wong :M. Y. Mok (*)
Q1 Department of Medicine, Queen Mary Hospital,
The University of Hong Kong,
Pok Fu Lam, Hong Kong, China
e-mail: temy@hkucc.hku.hk
M. H. Leung
Q1 Department of Medicine, Queen Elizabeth Hospital,
Kowloon, Hong Kong, China
Clin Rheumatol
DOI 10.1007/s10067-009-1315-8
JrnlID 10067_ArtID 1315_Proof# 1 - 06/11/2009
AUTHOR'S PROOF!
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
66 sedimentation rate (ESR) >40 mm/h at onset. Together with
67 a positive response to corticosteroid therapy, the sensitivity
68 of this diagnostic criteria has been reported to be as high as
69 99.5% [6].
70 However, a number of rheumatic conditions including
71 late onset rheumatoid arthritis (RA) [7], calcium pyrophos-
72 phate deposition disease, inflammatory myositis [8], and
73 fibromyalgia [9] may mimic PMR as they show similar
74 clinical features but carry different prognosis. Seventy-three
75 percent of a large cohort of 100 PMR patients have been
76 reported to develop cranial symptoms related to ischemic
77 events of giant cell arteries after a median of 3 weeks and
78 among these 16.4% of patients resulted in permanent visual
79 loss [10]. Furthermore, 6–17% of PMR patients have
80 been found to evolve into RA subsequently [7]. Anti-
81 cyclic citrullinated peptide (CCP) antibodies that have
82 recently been found to be a specific marker for RA [11]
83 have been suggested to be clinically useful in the
84 prediction of PMR patients who subsequently develop
85 into RA [12, 13]. Our study aimed to compare the clinical
86 characteristics of a Chinese cohort of PMR patients to a
87 Caucasian series and to examine the frequency of anti-
88 CCP antibodies in patients with and without subsequent
89 evolvement into RA.
90 Methodology
91 This study has been approved by the ethics committee of
92 the local institutional review board. All patients diagnosed
93 to have PMR by trained rheumatologists at a university
94 affiliated hospital and a large regional public hospital in
95 Hong Kong during 1997–2008 were identified through
96 the clinical data analysis and reporting system (Interna-
97 tional Classification of Diseases (ICD), i.e., ICD 9 Code
98 725), and their medical records were retrieved for
99 analysis. Demographic data, clinical features, treatment
100 regimen and response as well as laboratory investigations
101 including ESR, rheumatoid factor (RF) and anti-CCP
102 antibodies at disease onset were recorded. The clinical
103 characteristics of these patients were compared with
104 Caucasian series reported according to the criteria of Bird et
105 al. [3].
106 Measurement of RF and anti-CCP antibodies
107 RF was performed by latex-enhanced immunonephelometry
108 (BN ProSpec, Dade Behring, Germany) and was considered
109 positive at ≥15 IU/ml. Anti-CCP antibodies were measured by
110 a second-generation anti-CCP enzyme-linked immunosorbent
111 assay (Inova Diagnostic Inc., San Diego, CA, USA) according
112 to the manufacturer’s instructions. The cutoff value for
113 positive reaction was set at 20 arbitrary units (AU) as
114suggested by the manufacturer. The intra-assay variation of
115the assay was 3.5% with a high-level serum (175 AU) and 6%
116with a “low-level serum” (21 AU), and interassay variation
117was 6% for both sera. For patients who presented before
118the anti-CCP antibody assay was introduced into the
119hospital serology laboratory in early 2005, the earliest
120available serum samples after onset of presentation were
121retrieved and tested.
122Statistical analysis
123Statistical analysis was performed by SPSS 16.0 software
124(Chicago, IL, USA). Data were presented as mean±
125standard deviation (SD) unless otherwise stated. Chi-
126square test or Fisher’s exact test was performed for
127categorical variables. Mann–Whitney U test was used for
128comparison on continuous data between groups. Kaplan–
129Meier survival curve and log-rank test were used to
130compare the frequency of RF and anti-CCP antibody
131among patients who had and had not evolved into RA
132subsequently.
133Results
134Presenting features of PMR
135Forty-four (31 females and 13 males) patients of southern
136Chinese origin were identified from these two large
137regional hospitals during 1997–2008. The mean±SD age
138of these patients was 75.8±9.6 years with a mean duration
139of follow-up of 4.9±2.9 years. Table 1 shows a summary of
140the clinical features of these patients compared to those
141reported in a Caucasian series [6]. There was similar
142proportion of Chinese patients (75.0%) aged over 65 years
t1.1Table 1 Presenting features of PMR among the Chinese cohort
compared with a Caucasian series diagnosed according to the criteria
of Bird et al
t1.2Clinical Features Chinese
cohort
Caucasian
seriesa
p
value
t1.3Number (%) Number (%)
t1.4Age >65 33/44 (75.0) 171/213 (80.2) 0.40
t1.5Onset of illness <2 weeks
a 13/44 (29.5) 148/196 (75.5) <0.001
t1.6Bilateral shoulder
pain/stiffness
42/44 (95.5) 178/196 (90.8) 0.31
t1.7Bilateral upper arm tenderness 5/44 (11.4) 147/195 (75.5) <0.001
t1.8Stiffness >1 h 30/44 (68.2) 147/173 (84.9) 0.01
t1.9Weight loss/depression 13/44 (29.5) 85/213 (40.0) 0.20
t1.10Initial ESR >40 mm/h 44/44 (100) 158/165 (95.7) 0.17
a Refers to time taken for symptoms to reach their full-blown picture
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143 as the Caucasian counterpart (80.2%; p=0.40). Bilateral
144 shoulder pain/stiffness was the commonest symptom for
145 both cohorts (95.5% in Chinese and 90.8% in Caucasian,
146 p=0.31). However, Chinese patients had significantly
147 longer period before diagnosis (p<0.001), lesser bilateral
148 upper arm tenderness (p<0.001), and generalized stiffness
149 (p=0.01) compared to the Caucasian counterpart. All our
150 patients had ESR >40 mm/h at disease onset compared to
151 95.7% of the Western cohort (p=0.17), 25 (56.8%) among
152 whom had ESR level above 100 mm/h.
153 Response to treatment
154 Two patients (4.4%) responded to nonsteroidal anti-
155 inflammatory drugs (NSAIDs) alone. Most patients (39 of
156 44, 88.6%) were treated with prednisolone (mean daily
157 dose of 17.2±10.2 mg). There was a rapid response with
158 drop of ESR level by 50% or over from baseline within 2 to
159 3 months after treatment.
160 Evolvement into RA
161 Twelve (27.3%) PMR patients in our cohort subsequently
162 fulfilled the 1987 American College of Rheumatology
163 (ACR) criteria for RA [14] after a median duration of
164 2 months (range 1–24 months) from diagnosis of PMR. The
165 commonest ACR features fulfilled by these patients
166 included arthritis of three or more joint areas (100%) and
167 symmetrical arthritis (100%), followed by stiffness
168 (83.3%). Arthritis of hand joints and RF was present in
169 75% and 66.7% at the time of diagnosis of RA.
170 Predictive role of RF and anti-CCP antibodies in PMR
171 patients who evolved into RA
172 RF was checked in all patients and anti-CCP antibodies
173 in 21 patients. Among the 12 patients who had evolved
174 into RA, 66.7% were RF positive and 60% were anti-
175 CCP positive. RF and anti-CCP antibodies were present
176 in only 9.4% and 6.2% for those who had not evolved
177 into RA (n=32) for the period observed (Table 2). The
178 positive and negative predictive values for RF in the
179 development of RA were 72.7% and 87.9%, respectively,
180while those for anti-CCP antibodies were 75.0% and 88.2%,
181respectively.
182Figure 1 shows the Kaplan–Meier survival curve with
183evolvement into RA among PMR patients who were
184seropositive for RF (Fig. 1a) or anti-CCP antibodies
185(Fig. 1b) compared to those who were not. Patients who
186had positive serum RF (p<0.01) and anti-CCP antibodies
187(p=0.02) were more likely to develop RA during the period
188of observation.
189Discussion
190Our study showed that Chinese patients with PMR
191presented with similar features as the Caucasian counterpart
192including age at onset, bilateral shoulder pain or stiffness,
193constitutional symptoms, and ESR >40 mm/h. However,
194our patients were found to complain less of bilateral upper
195arm tenderness and generalized stiffness. Our patients also
196had longer duration of symptoms before seeking medical
197help. This may be due to the lack of awareness of an
198underlying rheumatic disease as nonspecific musculoskeletal
199rheumatism are frequent complaints in the elderly or that
200Chinese patients may demonstrate a different health care
201seeking behavior. Indeed, cultural and social influences have
202been demonstrated to affect the experience and adjustment to
203pain among subjects of different racial or ethnic groups [15].
204Our study showed that 27.3% of Chinese patients with
205initial diagnosis of PMR subsequently evolved into RA
206after a median of 2 months (range 1–24 months) since
207disease onset. This frequency was higher than the Western
208cohort where 6–17% of patients have been reported to
209develop into RA after a period of 3 to 5 years [12]. This
210may be related to the small sample size of our study and
211may also be explained by the more subjective items in the
212criteria of Bird et al. that lead to variations in different
213populations. Furthermore, PMR patients who had milder
214symptoms and those who readily respond to NSAIDs alone
215may have been managed at the primary care instead of
216being referred to our tertiary care units. It is also possible
217that we have included more patients with late onset RA into
218our cohort as PMR and elderly onset RA can be difficult to
219discriminate. A proportion of patients with late onset RA have
t2.2RF Anti-CCP antibodiesa
t2.3N (%) N (%)
t2.4Positive Negative Positive Negative
t2.5PMR with evolvement into RA 8/12 (66.7) 4/12 (33.3) 3/5 (60.0) 2/5 (40.0)
t2.6PMR without evolvement into RA 3/32 (9.4) 29/32 (90.6) 1/16 (6.2) 15/16 (93.8)
t2.1 Table 2 The frequency of RF
and anti-CCP antibodies
among PMR patients who
had evolved into RA and
those who had not
a Test performed by
second-generation
anti-CCP antibody assay
Clin Rheumatol
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220 been found to present with PMR features at disease onset with
221 prevalent involvement of the girdles, high ESR levels, and
222 good response to low-dose steroid treatment [7]. These patients
223 were typically seronegative for RF. A Japanese group has
224 attempted to refine criteria for detection of PMR with higher
225 sensitivity and specificity among their elderly subjects if the
226 patient fulfills all of the following: persistent bilateral
227 muscular pain for >2 weeks involving ≥2 of the neck,
228 shoulder girdle, upper arms, pelvis girdle, and thighs; normal
229 muscle enzyme level; ESR >40 mm/h; and absence of hand
230 joints involvement [16]. However, the sensitivity of diagnos-
231 ing PMR using such criteria on our cohort was 70% only.
232 We have explored the role of RF and anti-CCP anti-
233 bodies as predictive serological markers for subsequent
234 evolvement into RA. We found a high frequency of 67% of
235 RF in those PMR patients who developed into RA,
236 comparable to that observed in elderly onset RA [13]. RF
237 is still present in 9.4% of those patients who had not
238 evolved into RA and is likely related to the increased
239 prevalence of RF in the aged. Indeed, 10–15% of subjects
240older than 65 years of age have been reported to have
241positive RF [12]. On the other hand, anti-CCP antibodies
242were not present in 93.8% of patients who had not evolved
243into RA during the time of observation suggesting a high
244specificity and a role to predict development of RA. In this
245study, only a marginally better sensitivity and positive
246predictive value of anti-CCP antibodies was demonstrated
247compared to RF which is probably related to the small
248sample size of our study. Anti-CCP antibodies have
249recently been found to be a specific serological marker for
250RA. The second-generation anti-CCP antibodies assay has
251comparable sensitivity as serum RF (80%) while demon-
252strating almost absolute specificity for the diagnosis of RA
253[17]. The production of anti-CCP antibodies has been found
254to be an early process in RA development, and their
255presence is predictive of the development of the disease
256[10]. Our result complemented the conclusions from a
257previous study which showed that anti-CCP antibodies
258were useful in the differential diagnosis of elderly onset RA
259and PMR [13]. In that study, 65% elderly onset RA patients
260showed increased serum titer for anti-CCP antibodies
261compared to none of the healthy subjects and PMR
262patients. Thus, anti-CCP antibodies may be a clinically
263useful marker to be tested at the onset of patients with PMR
264such that these patients can be followed up for the
265development of RA which requires different treatment
266modalities and carries different prognosis.
267The average annual age- and sex-adjusted incidence of
268PMR aged 50 and older has been quoted as 54.8 per 100,000
269population in the USA [18]. There has not been any large
270scale epidemiological study in the Chinese population.
271However, in the small number of patients we were able to
272retrieve from the clinical data analysis and reporting system
273involving databases in two large public hospitals over an
27411-year-period, PMR does not appear to be a common
275condition in our locality. It remains possible that we are
276under diagnosing the condition given the lack of awareness at
277the levels of both patients and doctors and the absence of
278biomarker to aid clinical diagnosis. Education on the public,
279carers, and health care professionals is needed to raise
280awareness of this condition and the associated giant cell
281arteritis among different rheumatic problems encountered in
282the elderly so that they can be brought to medical attention
283earlier in their disease course. In conclusion, our study
284demonstrated that the spectrum of clinical features of PMR
285in Chinese patients is similar to that of the Caucasian
286counterpart. Larger prospective studies are warranted to
287delineate the role of clinical usefulness of anti-CCP antibodies
288in the early diagnosis and differentiation of PMR and RA.
289
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291kind help to furnish the English of this paper.
292Disclosures None.
Fig. 1 Kaplan–Meier survival curve showing evolvement of PMR
patients into RA among patients who were seropositive for RF (a) or
anti-CCP antibodies (b)
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